ArticleSurgery today2024
Treatment strategy for hepatocellular carcinoma recurrence in the transplant era: Focusing on the Japan criteria.
Article in Surgery today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A randomized comparative study evaluating water-jet with CUSA for parenchymal dissection in living-donor liver procurement: WORLD trial.International journal of surgery protocols · 2025Article
- Small intestinal metastasis of hepatocellular carcinoma diagnosed and resected as intestinal obstruction caused by a foreign body.Journal of surgical case reports · 2025Article
- Feasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial.International journal of surgery protocols · 2025Article
- Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients.Surgery today · 2025Article
- The impact of perioperative synbiotics treatment in living-donor liver transplantation after induction of early enteral nutrition.Surgery today · 2025Article
- Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.International journal of clinical oncology · 2025Review
- A case of simultaneous pancreatoduodenectomy and living donor liver transplantation for biliary cancer complicated with congenital biliary dilatation.Surgical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo clarify the Japan criteria (JC), as proposed in 2019, in order to identify the most appropriate treatment methods for hepatocellular carcinoma (HCC) recurrence and assess the feasibility of pre-living donor liver transplantation (LDLT) downstaging within these criteria.
methodsThe subjects of this study were 169 LDLT patients with HCC recurrence. We performed univariate and multivariate analyses of the factors contributing to HCC recurrence after LDLT and clarified the post-transplant outcomes of pre-LDLT downstaging.
resultsUnivariate and multivariate analysis identified beyond the JC (p = 0.0018) and a neutrophil-to-lymphocyte ratio > 2.01 (p = 0.029) as independent risk factors. Patients who met the JC had significantly higher recurrence-free and overall survival rates after LDLT (p < 0.0001) than those who did not (p = 0.0002). The post-transplant outcomes of patients within the JC after downstaging were significantly better than those of patients beyond the JC (p = 0.034) and equivalent to those within the JC without downstaging.
conclusionEven for HCC recurrence, the JC could play an important role in deciding on the best treatment strategy, and downstaging within the JC had good post-transplant outcomes.
Indexed as
Identifiers
37289265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.